Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Executive Summary
Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.
You may also be interested in...
Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication
New indication for second-line-plus acute lymphoblastic leukemia means Tecartus will compete with Novartis’s Kymriah, although the Gilead/Kite product is approved for older patient base.
Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy
Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.
Kymriah Poised For Expansion In Follicular Lymphoma, Leveling The Field With Yescarta
Novartis will present data from the pivotal Phase II ELARA trial of the CAR-T therapy in relapsed/refractory follicular lymphoma at ASCO.